|
Variable
|
NACT + RT group
|
CCRT group
|
P value
|
|---|
|
Total
|
98
|
116
| |
|
Age (years)
|
0.367
|
|
Median
|
44
|
45
| |
|
Range
|
17–70
|
16–70
| |
|
Gender [cases (%)]
|
0.179
|
|
Male
|
84 (85.7)
|
90 (77.6)
| |
|
Female
|
14 (14.3)
|
26 (22.4)
| |
|
Histology [cases (%)]
|
0.795
|
|
WHO II
|
5 (5.1)
|
8 (6.9)
| |
|
WHO III
|
93 (94.9)
|
108 (93.1)
| |
|
T stage [cases (%)]a
|
0.131
|
|
T3
|
43 (43.9)
|
64 (55.2)
| |
|
T4
|
55 (56.1)
|
52 (44.8)
| |
|
N stage [cases (%)]a
|
0.118
|
|
N0
|
34 (34.7)
|
47 (40.5)
| |
|
N1
|
64 (65.3)
|
69 (59.5)
| |
|
Total radiation dose (Gy)
|
0.721
|
|
Median
|
70
|
69
| |
|
Range
|
66–72
|
66–72
| |
|
Overall duration of radiotherapy (days)
|
0.674
|
|
Median
|
46
|
47
| |
|
Range
|
40–49
|
42–51
| |
-
WHO World Health Organization
-
aAccording to the Union for International Cancer Control/American Joint Committee on Cancer staging system, 7th edition
